GNVs, as therapeutic delivery vectors, transport biotinylated molecules and achieve targeted gene expression with minimal toxicity. The intranasal injection of GNVs encapsulated with the Stat3 inhibitor JSI-124 into GL26 tumor-bearing mice showed a significant inhibition of tumor growth. The intravenous administration of GNVs-folate (FA)-paclitaxel (PTX) showed enhanced targeted delivery and a significant reduction in tumor growth in the mouse CT26 colon cancer model and the human SW620 colon cancer SCID mouse model. No adverse reactions or major organ lesions were observed. The gene discussed is STAT3; the disease is neoplasm.